Stem definition | Drug id | CAS RN |
---|---|---|
serotonin (5-HT1) receptor agonists, sumatriptan derivatives | 2543 | 103628-46-2 |
Dose | Unit | Route |
---|---|---|
20 | mg | N |
50 | mg | O |
6 | mg | P |
25 | mg | R |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 21.40 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 22 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.68 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 14 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 1.70 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 19 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.83 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.70 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 28, 1992 | FDA | GLAXOSMITHKLINE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Product physical issue | 4111.33 | 11.52 | 911 | 42648 | 3421 | 50558144 |
Product dose omission issue | 1040.04 | 11.52 | 1016 | 42543 | 182822 | 50378743 |
Application site erythema | 560.14 | 11.52 | 192 | 43367 | 4346 | 50557219 |
Migraine | 494.45 | 11.52 | 453 | 43106 | 74827 | 50486738 |
Product quality issue | 491.55 | 11.52 | 315 | 43244 | 30543 | 50531022 |
Application site burn | 376.73 | 11.52 | 95 | 43464 | 681 | 50560884 |
Device deployment issue | 332.86 | 11.52 | 122 | 43437 | 3374 | 50558191 |
Device malfunction | 330.06 | 11.52 | 189 | 43370 | 14932 | 50546633 |
Application site pain | 326.63 | 11.52 | 123 | 43436 | 3675 | 50557890 |
Application site discolouration | 263.42 | 11.52 | 71 | 43488 | 679 | 50560886 |
Device issue | 257.89 | 11.52 | 179 | 43380 | 19793 | 50541772 |
Application site paraesthesia | 191.73 | 11.52 | 36 | 43523 | 39 | 50561526 |
Accidental exposure to product | 143.83 | 11.52 | 135 | 43424 | 22922 | 50538643 |
Application site urticaria | 136.77 | 11.52 | 34 | 43525 | 228 | 50561337 |
Application site rash | 131.87 | 11.52 | 56 | 43503 | 2301 | 50559264 |
Application site irritation | 123.42 | 11.52 | 48 | 43511 | 1567 | 50559998 |
Medication overuse headache | 119.52 | 11.52 | 37 | 43522 | 598 | 50560967 |
Colitis ischaemic | 117.73 | 11.52 | 83 | 43476 | 9400 | 50552165 |
Application site warmth | 113.88 | 11.52 | 27 | 43532 | 144 | 50561421 |
Application site pruritus | 109.79 | 11.52 | 57 | 43502 | 3702 | 50557863 |
Headache | 99.53 | 11.52 | 760 | 42799 | 505775 | 50055790 |
Death | 96.58 | 11.52 | 83 | 43476 | 325296 | 50236269 |
Needle issue | 95.74 | 11.52 | 66 | 43493 | 7209 | 50554356 |
Arteriospasm coronary | 94.83 | 11.52 | 50 | 43509 | 3352 | 50558213 |
Anxiety | 89.10 | 11.52 | 345 | 43214 | 177261 | 50384304 |
Application site scar | 81.84 | 11.52 | 22 | 43537 | 208 | 50561357 |
Injection site pain | 78.66 | 11.52 | 242 | 43317 | 110782 | 50450783 |
Application site vesicles | 78.49 | 11.52 | 33 | 43526 | 1322 | 50560243 |
Paraesthesia | 76.89 | 11.52 | 253 | 43306 | 119990 | 50441575 |
Injection site haemorrhage | 74.64 | 11.52 | 92 | 43467 | 21254 | 50540311 |
Application site swelling | 73.04 | 11.52 | 24 | 43535 | 474 | 50561091 |
Glossodynia | 71.41 | 11.52 | 8 | 43551 | 115561 | 50446004 |
Reversible cerebral vasoconstriction syndrome | 70.24 | 11.52 | 35 | 43524 | 2084 | 50559481 |
Throat tightness | 69.93 | 11.52 | 88 | 43471 | 20759 | 50540806 |
IIIrd nerve paresis | 66.79 | 11.52 | 17 | 43542 | 127 | 50561438 |
Product substitution issue | 66.77 | 11.52 | 71 | 43488 | 13986 | 50547579 |
Acute kidney injury | 65.40 | 11.52 | 60 | 43499 | 227998 | 50333567 |
Device power source issue | 65.12 | 11.52 | 22 | 43537 | 475 | 50561090 |
Wrong technique in product usage process | 64.97 | 11.52 | 146 | 43413 | 55364 | 50506201 |
Systemic lupus erythematosus | 63.37 | 11.52 | 21 | 43538 | 140601 | 50420964 |
Muscle twitching | 63.02 | 11.52 | 72 | 43487 | 15359 | 50546206 |
Anaemia | 61.69 | 11.52 | 76 | 43483 | 252380 | 50309185 |
Cerebral vasoconstriction | 60.28 | 11.52 | 25 | 43534 | 967 | 50560598 |
Product leakage | 59.80 | 11.52 | 21 | 43538 | 511 | 50561054 |
Application site exfoliation | 58.72 | 11.52 | 18 | 43541 | 281 | 50561284 |
Coronary artery dissection | 56.95 | 11.52 | 22 | 43537 | 705 | 50560860 |
Infusion related reaction | 56.95 | 11.52 | 38 | 43521 | 169519 | 50392046 |
Arthropathy | 54.93 | 11.52 | 34 | 43525 | 157872 | 50403693 |
Wound | 54.82 | 11.52 | 12 | 43547 | 105782 | 50455783 |
Contraindicated product administered | 54.75 | 11.52 | 30 | 43529 | 148928 | 50412637 |
Application site dryness | 54.60 | 11.52 | 15 | 43544 | 155 | 50561410 |
Depression | 53.32 | 11.52 | 282 | 43277 | 165141 | 50396424 |
Serotonin syndrome | 52.69 | 11.52 | 84 | 43475 | 24629 | 50536936 |
Drug ineffective | 51.96 | 11.52 | 990 | 42569 | 818343 | 49743222 |
Cholecystitis chronic | 51.62 | 11.52 | 52 | 43507 | 9617 | 50551948 |
Application site reaction | 51.39 | 11.52 | 20 | 43539 | 654 | 50560911 |
Product complaint | 51.10 | 11.52 | 56 | 43503 | 11410 | 50550155 |
Treatment failure | 50.18 | 11.52 | 28 | 43531 | 137609 | 50423956 |
Emotional distress | 48.63 | 11.52 | 88 | 43471 | 28575 | 50532990 |
Dizziness | 48.56 | 11.52 | 483 | 43076 | 345886 | 50215679 |
Abdominal discomfort | 48.35 | 11.52 | 78 | 43481 | 231563 | 50330002 |
Application site scab | 48.32 | 11.52 | 14 | 43545 | 178 | 50561387 |
Concussion | 48.20 | 11.52 | 45 | 43514 | 7583 | 50553982 |
Device leakage | 47.78 | 11.52 | 40 | 43519 | 5838 | 50555727 |
Post-traumatic neck syndrome | 47.44 | 11.52 | 26 | 43533 | 1884 | 50559681 |
Somnambulism | 47.42 | 11.52 | 37 | 43522 | 4887 | 50556678 |
Rheumatoid arthritis | 47.36 | 11.52 | 63 | 43496 | 202487 | 50359078 |
Febrile neutropenia | 46.86 | 11.52 | 13 | 43546 | 97654 | 50463911 |
Incorrect dose administered by device | 46.84 | 11.52 | 32 | 43527 | 3443 | 50558122 |
Renal infarct | 46.67 | 11.52 | 23 | 43536 | 1337 | 50560228 |
Pituitary tumour benign | 46.33 | 11.52 | 25 | 43534 | 1756 | 50559809 |
Chest discomfort | 45.51 | 11.52 | 179 | 43380 | 92543 | 50469022 |
Lower respiratory tract infection | 45.07 | 11.52 | 13 | 43546 | 95188 | 50466377 |
Injection site bruising | 44.47 | 11.52 | 98 | 43461 | 36670 | 50524895 |
Hostility | 43.55 | 11.52 | 24 | 43535 | 1758 | 50559807 |
Cardiac failure | 42.84 | 11.52 | 7 | 43552 | 76033 | 50485532 |
Libido increased | 42.59 | 11.52 | 21 | 43538 | 1222 | 50560343 |
Neutropenia | 42.30 | 11.52 | 39 | 43520 | 147926 | 50413639 |
Endometriosis | 42.26 | 11.52 | 32 | 43527 | 4043 | 50557522 |
Soft tissue injury | 41.90 | 11.52 | 22 | 43537 | 1462 | 50560103 |
Renal impairment | 40.39 | 11.52 | 8 | 43551 | 75653 | 50485912 |
Application site inflammation | 38.89 | 11.52 | 14 | 43545 | 367 | 50561198 |
Tension headache | 38.85 | 11.52 | 26 | 43533 | 2705 | 50558860 |
Joint swelling | 38.84 | 11.52 | 97 | 43462 | 245189 | 50316376 |
Disease progression | 38.71 | 11.52 | 17 | 43542 | 95849 | 50465716 |
Expired product administered | 38.41 | 11.52 | 34 | 43525 | 5348 | 50556217 |
Application site bruise | 38.08 | 11.52 | 13 | 43546 | 290 | 50561275 |
Off label use | 37.99 | 11.52 | 246 | 43313 | 474180 | 50087385 |
Nightmare | 37.53 | 11.52 | 57 | 43502 | 16029 | 50545536 |
Atrial fibrillation | 36.64 | 11.52 | 21 | 43538 | 101724 | 50459841 |
Pneumonia | 36.30 | 11.52 | 185 | 43374 | 378216 | 50183349 |
Sternal fracture | 35.76 | 11.52 | 22 | 43537 | 1980 | 50559585 |
Clonus | 35.16 | 11.52 | 29 | 43530 | 4146 | 50557419 |
Hypotension | 34.33 | 11.52 | 97 | 43462 | 235372 | 50326193 |
Suicidal ideation | 33.99 | 11.52 | 115 | 43444 | 55270 | 50506295 |
Swelling | 33.72 | 11.52 | 77 | 43482 | 200795 | 50360770 |
Alopecia | 33.52 | 11.52 | 104 | 43455 | 244943 | 50316622 |
Nausea | 33.49 | 11.52 | 818 | 42741 | 704580 | 49856985 |
Diarrhoea | 33.37 | 11.52 | 335 | 43224 | 588141 | 49973424 |
Feeling abnormal | 33.20 | 11.52 | 203 | 43356 | 125289 | 50436276 |
Angle closure glaucoma | 32.93 | 11.52 | 21 | 43538 | 2013 | 50559552 |
Incorrect route of product administration | 32.54 | 11.52 | 58 | 43501 | 18608 | 50542957 |
Drug specific antibody | 32.46 | 11.52 | 20 | 43539 | 1805 | 50559760 |
Secondary adrenocortical insufficiency | 32.43 | 11.52 | 17 | 43542 | 1126 | 50560439 |
Haemoglobin decreased | 32.42 | 11.52 | 37 | 43522 | 127179 | 50434386 |
Muscle tightness | 32.27 | 11.52 | 42 | 43517 | 10238 | 50551327 |
Hypoaesthesia | 31.26 | 11.52 | 202 | 43357 | 127055 | 50434510 |
Therapeutic response unexpected | 31.08 | 11.52 | 52 | 43507 | 15863 | 50545702 |
Infection | 30.93 | 11.52 | 64 | 43495 | 172890 | 50388675 |
Pancytopenia | 30.75 | 11.52 | 17 | 43542 | 84013 | 50477552 |
Transient global amnesia | 30.59 | 11.52 | 12 | 43547 | 401 | 50561164 |
Dysgeusia | 30.53 | 11.52 | 88 | 43471 | 38828 | 50522737 |
Pre-existing condition improved | 30.48 | 11.52 | 34 | 43525 | 7063 | 50554502 |
Device defective | 30.44 | 11.52 | 17 | 43542 | 1278 | 50560287 |
Chest pain | 29.40 | 11.52 | 256 | 43303 | 176626 | 50384939 |
Hyponatraemia | 29.09 | 11.52 | 24 | 43535 | 96115 | 50465450 |
Pharyngeal swelling | 28.97 | 11.52 | 27 | 43532 | 4539 | 50557026 |
Peripheral swelling | 28.44 | 11.52 | 87 | 43472 | 205849 | 50355716 |
Platelet count decreased | 28.24 | 11.52 | 27 | 43532 | 100699 | 50460866 |
Hot flush | 28.24 | 11.52 | 93 | 43466 | 44076 | 50517489 |
Application site discomfort | 28.20 | 11.52 | 11 | 43548 | 362 | 50561203 |
Hyperkalaemia | 28.06 | 11.52 | 4 | 43555 | 48085 | 50513480 |
Oxygen saturation decreased | 28.01 | 11.52 | 14 | 43545 | 73234 | 50488331 |
Hepatic enzyme increased | 27.95 | 11.52 | 47 | 43512 | 137333 | 50424232 |
Renal tubular acidosis | 27.76 | 11.52 | 17 | 43542 | 1517 | 50560048 |
Interstitial lung disease | 27.60 | 11.52 | 6 | 43553 | 53170 | 50508395 |
Sepsis | 27.48 | 11.52 | 45 | 43514 | 132880 | 50428685 |
Application site erosion | 27.38 | 11.52 | 9 | 43550 | 178 | 50561387 |
Migraine without aura | 27.19 | 11.52 | 10 | 43549 | 279 | 50561286 |
Drug hypersensitivity | 26.41 | 11.52 | 331 | 43228 | 250679 | 50310886 |
Malignant neoplasm progression | 26.08 | 11.52 | 13 | 43546 | 68111 | 50493454 |
Vasospasm | 25.62 | 11.52 | 12 | 43547 | 623 | 50560942 |
Hyperprolactinaemia | 25.51 | 11.52 | 22 | 43537 | 3343 | 50558222 |
General physical health deterioration | 25.21 | 11.52 | 53 | 43506 | 142381 | 50419184 |
Gastrointestinal haemorrhage | 25.18 | 11.52 | 16 | 43543 | 73305 | 50488260 |
Underdose | 24.46 | 11.52 | 54 | 43505 | 20224 | 50541341 |
Poor quality sleep | 24.37 | 11.52 | 48 | 43511 | 16598 | 50544967 |
Cluster headache | 24.37 | 11.52 | 11 | 43548 | 524 | 50561041 |
Blood creatinine increased | 24.32 | 11.52 | 18 | 43541 | 76142 | 50485423 |
Pleural effusion | 23.82 | 11.52 | 21 | 43538 | 81433 | 50480132 |
Injection site laceration | 23.34 | 11.52 | 7 | 43552 | 101 | 50561464 |
Product use issue | 22.95 | 11.52 | 60 | 43499 | 149415 | 50412150 |
Impaired healing | 22.93 | 11.52 | 16 | 43543 | 69770 | 50491795 |
Synovitis | 22.85 | 11.52 | 45 | 43514 | 123820 | 50437745 |
Injury | 22.82 | 11.52 | 93 | 43466 | 48832 | 50512733 |
Personality disorder | 22.62 | 11.52 | 23 | 43536 | 4301 | 50557264 |
Tremor | 22.14 | 11.52 | 172 | 43387 | 114731 | 50446834 |
Cardiac failure congestive | 22.08 | 11.52 | 24 | 43535 | 84358 | 50477207 |
Application site papules | 22.02 | 11.52 | 6 | 43553 | 60 | 50561505 |
Vasoconstriction | 21.95 | 11.52 | 10 | 43549 | 487 | 50561078 |
Photophobia | 21.88 | 11.52 | 43 | 43516 | 14844 | 50546721 |
Multiple sclerosis | 21.87 | 11.52 | 52 | 43507 | 20441 | 50541124 |
Septic shock | 21.75 | 11.52 | 11 | 43548 | 57164 | 50504401 |
Rash | 21.55 | 11.52 | 257 | 43302 | 437214 | 50124351 |
Palpitations | 21.38 | 11.52 | 147 | 43412 | 94359 | 50467206 |
Paraesthesia oral | 21.33 | 11.52 | 38 | 43521 | 12183 | 50549382 |
Stomatitis | 21.23 | 11.52 | 34 | 43525 | 101310 | 50460255 |
Renal failure | 21.20 | 11.52 | 37 | 43522 | 106596 | 50454969 |
Eyelid ptosis | 20.56 | 11.52 | 26 | 43533 | 6161 | 50555404 |
Dependence | 20.06 | 11.52 | 15 | 43544 | 1860 | 50559705 |
Neonatal respiratory distress | 19.73 | 11.52 | 8 | 43551 | 292 | 50561273 |
Somnolence | 19.67 | 11.52 | 212 | 43347 | 154773 | 50406792 |
Neck pain | 19.53 | 11.52 | 99 | 43460 | 56968 | 50504597 |
Migraine with aura | 19.51 | 11.52 | 16 | 43543 | 2269 | 50559296 |
Phonophobia | 19.50 | 11.52 | 8 | 43551 | 301 | 50561264 |
Basilar migraine | 19.23 | 11.52 | 5 | 43554 | 41 | 50561524 |
Irritability | 19.21 | 11.52 | 61 | 43498 | 28365 | 50533200 |
Muscle spasms | 18.95 | 11.52 | 178 | 43381 | 125375 | 50436190 |
Pyrexia | 18.85 | 11.52 | 223 | 43336 | 379980 | 50181585 |
Narcolepsy | 18.84 | 11.52 | 12 | 43547 | 1148 | 50560417 |
Sunburn | 18.80 | 11.52 | 16 | 43543 | 2387 | 50559178 |
Product adhesion issue | 18.79 | 11.52 | 21 | 43538 | 4371 | 50557194 |
Large intestinal ulcer haemorrhage | 18.73 | 11.52 | 6 | 43553 | 109 | 50561456 |
Multiple organ dysfunction syndrome | 18.68 | 11.52 | 10 | 43549 | 50327 | 50511238 |
Osteonecrosis of jaw | 18.30 | 11.52 | 3 | 43556 | 32523 | 50529042 |
Spleen congestion | 18.28 | 11.52 | 6 | 43553 | 118 | 50561447 |
Biliary dyskinesia | 17.98 | 11.52 | 16 | 43543 | 2534 | 50559031 |
Cerebral venous thrombosis | 17.89 | 11.52 | 14 | 43545 | 1857 | 50559708 |
Injection site injury | 17.74 | 11.52 | 9 | 43550 | 557 | 50561008 |
Incorrect product administration duration | 17.70 | 11.52 | 30 | 43529 | 9245 | 50552320 |
Decreased appetite | 17.68 | 11.52 | 101 | 43458 | 200822 | 50360743 |
Thrombocytopenia | 17.56 | 11.52 | 54 | 43505 | 127619 | 50433946 |
Middle insomnia | 17.51 | 11.52 | 31 | 43528 | 9890 | 50551675 |
Post-traumatic stress disorder | 17.43 | 11.52 | 20 | 43539 | 4283 | 50557282 |
Cough | 17.32 | 11.52 | 129 | 43430 | 241135 | 50320430 |
Device use error | 17.29 | 11.52 | 22 | 43537 | 5244 | 50556321 |
Blood testosterone increased | 17.16 | 11.52 | 6 | 43553 | 144 | 50561421 |
Vision blurred | 17.00 | 11.52 | 121 | 43438 | 78526 | 50483039 |
International normalised ratio increased | 16.87 | 11.52 | 8 | 43551 | 43144 | 50518421 |
Lactic acidosis | 16.83 | 11.52 | 4 | 43555 | 33351 | 50528214 |
Drug dependence | 16.79 | 11.52 | 46 | 43513 | 19713 | 50541852 |
Hip arthroplasty | 16.70 | 11.52 | 3 | 43556 | 30426 | 50531139 |
Subclavian artery thrombosis | 16.46 | 11.52 | 6 | 43553 | 163 | 50561402 |
Drug effect less than expected | 16.25 | 11.52 | 8 | 43551 | 464 | 50561101 |
Hyperacusis | 16.18 | 11.52 | 13 | 43546 | 1791 | 50559774 |
Meningoradiculitis | 16.14 | 11.52 | 5 | 43554 | 81 | 50561484 |
Application site dermatitis | 16.13 | 11.52 | 6 | 43553 | 173 | 50561392 |
Sleep talking | 15.99 | 11.52 | 10 | 43549 | 926 | 50560639 |
Memory impairment | 15.95 | 11.52 | 120 | 43439 | 79240 | 50482325 |
Red blood cell sedimentation rate increased | 15.93 | 11.52 | 3 | 43556 | 29413 | 50532152 |
Superior sagittal sinus thrombosis | 15.85 | 11.52 | 9 | 43550 | 698 | 50560867 |
Bipolar disorder | 15.84 | 11.52 | 24 | 43535 | 6733 | 50554832 |
Seizure | 15.78 | 11.52 | 163 | 43396 | 117711 | 50443854 |
Neoplasm progression | 15.73 | 11.52 | 3 | 43556 | 29154 | 50532411 |
Gastrooesophageal reflux disease | 15.61 | 11.52 | 116 | 43443 | 76312 | 50485253 |
Major depression | 15.50 | 11.52 | 24 | 43535 | 6860 | 50554705 |
Transverse sinus thrombosis | 15.46 | 11.52 | 8 | 43551 | 516 | 50561049 |
Injury associated with device | 15.26 | 11.52 | 16 | 43543 | 3101 | 50558464 |
Lichen planus | 15.13 | 11.52 | 13 | 43546 | 1966 | 50559599 |
Cerebral venous sinus thrombosis | 14.92 | 11.52 | 12 | 43547 | 1656 | 50559909 |
Hyperreflexia | 14.67 | 11.52 | 20 | 43539 | 5098 | 50556467 |
Bone marrow failure | 14.57 | 11.52 | 3 | 43556 | 27621 | 50533944 |
Hepatic function abnormal | 14.50 | 11.52 | 5 | 43554 | 32676 | 50528889 |
Gastrointestinal disorder | 14.42 | 11.52 | 38 | 43521 | 94418 | 50467147 |
Nipple pain | 14.42 | 11.52 | 6 | 43553 | 234 | 50561331 |
Peripheral nerve injury | 14.40 | 11.52 | 7 | 43552 | 395 | 50561170 |
Trismus | 14.31 | 11.52 | 16 | 43543 | 3332 | 50558233 |
Burning sensation | 14.28 | 11.52 | 77 | 43482 | 45369 | 50516196 |
Gallbladder disorder | 14.25 | 11.52 | 39 | 43520 | 16703 | 50544862 |
Therapeutic response shortened | 14.24 | 11.52 | 24 | 43535 | 7365 | 50554200 |
Ischaemic cerebral infarction | 14.10 | 11.52 | 10 | 43549 | 1143 | 50560422 |
Pancreatic failure | 14.05 | 11.52 | 9 | 43550 | 869 | 50560696 |
Potassium wasting nephropathy | 14.02 | 11.52 | 4 | 43555 | 48 | 50561517 |
Melaena | 14.00 | 11.52 | 3 | 43556 | 26861 | 50534704 |
Alanine aminotransferase increased | 13.91 | 11.52 | 35 | 43524 | 88324 | 50473241 |
Rash maculo-papular | 13.83 | 11.52 | 3 | 43556 | 26638 | 50534927 |
Multiple sclerosis relapse | 13.64 | 11.52 | 73 | 43486 | 42891 | 50518674 |
Cardio-respiratory arrest | 13.37 | 11.52 | 16 | 43543 | 53876 | 50507689 |
Pneumonia aspiration | 13.32 | 11.52 | 5 | 43554 | 30999 | 50530566 |
Maternal exposure during pregnancy | 13.16 | 11.52 | 82 | 43477 | 159696 | 50401869 |
Slow speech | 13.15 | 11.52 | 10 | 43549 | 1272 | 50560293 |
Hyperhidrosis | 13.10 | 11.52 | 126 | 43433 | 89300 | 50472265 |
Post viral fatigue syndrome | 13.09 | 11.52 | 6 | 43553 | 296 | 50561269 |
Meningitis aseptic | 13.09 | 11.52 | 17 | 43542 | 4135 | 50557430 |
Gallbladder injury | 13.06 | 11.52 | 10 | 43549 | 1284 | 50560281 |
Cholestasis | 12.91 | 11.52 | 3 | 43556 | 25398 | 50536167 |
Deep vein thrombosis | 12.63 | 11.52 | 107 | 43452 | 73197 | 50488368 |
Sensory disturbance | 12.60 | 11.52 | 30 | 43529 | 11799 | 50549766 |
Toxicity to various agents | 12.38 | 11.52 | 120 | 43439 | 212379 | 50349186 |
Hepatotoxicity | 12.37 | 11.52 | 4 | 43555 | 27222 | 50534343 |
Product packaging quantity issue | 12.36 | 11.52 | 9 | 43550 | 1071 | 50560494 |
Blood HIV RNA increased | 12.34 | 11.52 | 7 | 43552 | 542 | 50561023 |
Nasal discomfort | 12.33 | 11.52 | 16 | 43543 | 3888 | 50557677 |
Influenza like illness | 12.18 | 11.52 | 88 | 43471 | 57371 | 50504194 |
Chemical burn | 12.08 | 11.52 | 6 | 43553 | 355 | 50561210 |
Knee arthroplasty | 12.06 | 11.52 | 8 | 43551 | 35838 | 50525727 |
Respiratory disorder | 11.86 | 11.52 | 6 | 43553 | 31181 | 50530384 |
Ovarian neoplasm | 11.85 | 11.52 | 8 | 43551 | 844 | 50560721 |
Complement factor C4 decreased | 11.85 | 11.52 | 5 | 43554 | 202 | 50561363 |
Premature delivery | 11.63 | 11.52 | 3 | 43556 | 23660 | 50537905 |
Pharyngeal oedema | 11.53 | 11.52 | 31 | 43528 | 13134 | 50548431 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Product physical issue | 992.79 | 18.11 | 199 | 6983 | 1889 | 29565456 |
Product dose omission issue | 243.88 | 18.11 | 195 | 6987 | 96188 | 29471157 |
Migraine | 128.65 | 18.11 | 62 | 7120 | 12368 | 29554977 |
Product quality issue | 122.66 | 18.11 | 65 | 7117 | 15830 | 29551515 |
Device deployment issue | 98.02 | 18.11 | 18 | 7164 | 100 | 29567245 |
Headache | 79.29 | 18.11 | 147 | 7035 | 173860 | 29393485 |
Arteriospasm coronary | 71.69 | 18.11 | 26 | 7156 | 2539 | 29564806 |
Device malfunction | 63.36 | 18.11 | 34 | 7148 | 8473 | 29558872 |
Device issue | 57.68 | 18.11 | 31 | 7151 | 7749 | 29559596 |
Serotonin syndrome | 51.76 | 18.11 | 39 | 7143 | 17473 | 29549872 |
Throat tightness | 49.08 | 18.11 | 27 | 7155 | 7064 | 29560281 |
IIIrd nerve paresis | 44.63 | 18.11 | 9 | 7173 | 87 | 29567258 |
Accidental exposure to product | 41.08 | 18.11 | 28 | 7154 | 10725 | 29556620 |
Hyperhidrosis | 37.71 | 18.11 | 61 | 7121 | 64479 | 29502866 |
Injection site pain | 36.25 | 18.11 | 42 | 7140 | 32404 | 29534941 |
Cluster headache | 34.52 | 18.11 | 10 | 7172 | 476 | 29566869 |
Application site pain | 32.43 | 18.11 | 13 | 7169 | 1666 | 29565679 |
Medication overuse headache | 31.18 | 18.11 | 7 | 7175 | 117 | 29567228 |
Myofascial pain syndrome | 29.41 | 18.11 | 8 | 7174 | 302 | 29567043 |
Acute kidney injury | 29.23 | 18.11 | 14 | 7168 | 265253 | 29302092 |
Needle issue | 27.46 | 18.11 | 16 | 7166 | 4667 | 29562678 |
Application site burn | 27.44 | 18.11 | 7 | 7175 | 205 | 29567140 |
Xanthelasma | 27.03 | 18.11 | 6 | 7176 | 95 | 29567250 |
Gastrointestinal tract irritation | 26.82 | 18.11 | 7 | 7175 | 225 | 29567120 |
Anophthalmos | 26.52 | 18.11 | 4 | 7178 | 4 | 29567341 |
Congenital genital malformation male | 24.90 | 18.11 | 4 | 7178 | 8 | 29567337 |
Facial pain | 24.90 | 18.11 | 11 | 7171 | 1794 | 29565551 |
Foetal malnutrition | 23.96 | 18.11 | 5 | 7177 | 58 | 29567287 |
Burns second degree | 23.77 | 18.11 | 7 | 7175 | 353 | 29566992 |
Autonomic dysreflexia | 23.16 | 18.11 | 5 | 7177 | 69 | 29567276 |
Death | 21.71 | 18.11 | 31 | 7151 | 342053 | 29225292 |
Drug ineffective | 21.49 | 18.11 | 156 | 7026 | 363014 | 29204331 |
Capillaritis | 21.28 | 18.11 | 5 | 7177 | 103 | 29567242 |
Foetal exposure during pregnancy | 21.12 | 18.11 | 33 | 7149 | 33834 | 29533511 |
Muscle tightness | 20.73 | 18.11 | 13 | 7169 | 4325 | 29563020 |
Electrocardiogram ST segment elevation | 20.32 | 18.11 | 13 | 7169 | 4479 | 29562866 |
Craniosynostosis | 20.29 | 18.11 | 6 | 7176 | 307 | 29567038 |
Application site erythema | 20.28 | 18.11 | 10 | 7172 | 2089 | 29565256 |
Irritable bowel syndrome | 19.94 | 18.11 | 11 | 7171 | 2890 | 29564455 |
Injection site haemorrhage | 19.03 | 18.11 | 16 | 7166 | 8370 | 29558975 |
Paraesthesia | 18.99 | 18.11 | 41 | 7141 | 53804 | 29513541 |
Tobacco abuse | 18.93 | 18.11 | 6 | 7176 | 388 | 29566957 |
Anxiety | 18.51 | 18.11 | 54 | 7128 | 85311 | 29482034 |
Aphasia | 18.39 | 18.11 | 23 | 7159 | 19175 | 29548170 |
Insomnia | 18.15 | 18.11 | 55 | 7127 | 88706 | 29478639 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Product physical issue | 1348.01 | 12.34 | 329 | 37679 | 3120 | 64457604 |
Migraine | 527.96 | 12.34 | 373 | 37635 | 62304 | 64398420 |
Application site erythema | 404.71 | 12.34 | 138 | 37870 | 4551 | 64456173 |
Product dose omission issue | 321.94 | 12.34 | 479 | 37529 | 194268 | 64266456 |
Application site burn | 285.93 | 12.34 | 71 | 37937 | 725 | 64459999 |
Application site pain | 238.59 | 12.34 | 91 | 37917 | 4157 | 64456567 |
Product quality issue | 227 | 12.34 | 167 | 37841 | 29632 | 64431092 |
Application site discolouration | 193.71 | 12.34 | 51 | 37957 | 669 | 64460055 |
Device malfunction | 186.59 | 12.34 | 121 | 37887 | 17512 | 64443212 |
Application site paraesthesia | 181.44 | 12.34 | 32 | 37976 | 37 | 64460687 |
Headache | 159.65 | 12.34 | 675 | 37333 | 528792 | 63931932 |
Arteriospasm coronary | 151.90 | 12.34 | 71 | 37937 | 5394 | 64455330 |
Accidental exposure to product | 147.18 | 12.34 | 123 | 37885 | 26241 | 64434483 |
Medication overuse headache | 124.81 | 12.34 | 36 | 37972 | 674 | 64460050 |
IIIrd nerve paresis | 117.60 | 12.34 | 26 | 37982 | 151 | 64460573 |
Throat tightness | 116.91 | 12.34 | 102 | 37906 | 23058 | 64437666 |
Acute kidney injury | 114.74 | 12.34 | 61 | 37947 | 449179 | 64011545 |
Colitis ischaemic | 110.83 | 12.34 | 79 | 37929 | 13335 | 64447389 |
Anxiety | 103.71 | 12.34 | 308 | 37700 | 202341 | 64258383 |
Application site pruritus | 101.52 | 12.34 | 47 | 37961 | 3492 | 64457232 |
Application site irritation | 100.29 | 12.34 | 37 | 37971 | 1539 | 64459185 |
Application site warmth | 100.21 | 12.34 | 23 | 37985 | 162 | 64460562 |
Device deployment issue | 98.49 | 12.34 | 43 | 37965 | 2783 | 64457941 |
Paraesthesia | 93.50 | 12.34 | 229 | 37779 | 134293 | 64326431 |
Death | 92.54 | 12.34 | 89 | 37919 | 482616 | 63978108 |
Application site rash | 89.10 | 12.34 | 36 | 37972 | 1918 | 64458806 |
Application site urticaria | 89 | 12.34 | 22 | 37986 | 220 | 64460504 |
Reversible cerebral vasoconstriction syndrome | 86.08 | 12.34 | 37 | 37971 | 2305 | 64458419 |
Device issue | 80.28 | 12.34 | 82 | 37926 | 22566 | 64438158 |
Serotonin syndrome | 80.05 | 12.34 | 107 | 37901 | 39175 | 64421549 |
Wrong technique in product usage process | 79.94 | 12.34 | 140 | 37868 | 64834 | 64395890 |
Anaemia | 77.08 | 12.34 | 66 | 37942 | 378614 | 64082110 |
Application site swelling | 71.86 | 12.34 | 23 | 37985 | 619 | 64460105 |
Application site scar | 68.24 | 12.34 | 17 | 37991 | 176 | 64460548 |
Cerebral vasoconstriction | 67.98 | 12.34 | 26 | 37982 | 1196 | 64459528 |
Muscle twitching | 64.11 | 12.34 | 67 | 37941 | 18931 | 64441793 |
Dizziness | 62.27 | 12.34 | 450 | 37558 | 429713 | 64031011 |
Depression | 60.66 | 12.34 | 241 | 37767 | 183050 | 64277674 |
Endometriosis | 58.76 | 12.34 | 30 | 37978 | 2762 | 64457962 |
Emotional distress | 58.40 | 12.34 | 88 | 37920 | 35950 | 64424774 |
Cardiac failure | 56.68 | 12.34 | 6 | 38002 | 132367 | 64328357 |
Chest discomfort | 56.05 | 12.34 | 173 | 37835 | 115933 | 64344791 |
Application site vesicles | 55.65 | 12.34 | 23 | 37985 | 1299 | 64459425 |
Febrile neutropenia | 54.80 | 12.34 | 21 | 37987 | 187636 | 64273088 |
Injection site pain | 54.71 | 12.34 | 167 | 37841 | 111241 | 64349483 |
Post-traumatic neck syndrome | 53.75 | 12.34 | 25 | 37983 | 1877 | 64458847 |
Coronary artery dissection | 52.92 | 12.34 | 20 | 37988 | 890 | 64459834 |
Pneumonia | 52.27 | 12.34 | 163 | 37845 | 559413 | 63901311 |
Pituitary tumour benign | 52.24 | 12.34 | 26 | 37982 | 2267 | 64458457 |
Cholecystitis chronic | 51.13 | 12.34 | 43 | 37965 | 9244 | 64451480 |
Nausea | 48.54 | 12.34 | 689 | 37319 | 785111 | 63675613 |
Soft tissue injury | 48.53 | 12.34 | 22 | 37986 | 1557 | 64459167 |
Muscle tightness | 48.29 | 12.34 | 45 | 37963 | 11070 | 64449654 |
Drug ineffective | 48.09 | 12.34 | 727 | 37281 | 839520 | 63621204 |
Injection site haemorrhage | 47.73 | 12.34 | 65 | 37943 | 24213 | 64436511 |
Chest pain | 47.11 | 12.34 | 268 | 37740 | 235712 | 64225012 |
Sepsis | 46.98 | 12.34 | 40 | 37968 | 230301 | 64230423 |
Cluster headache | 46.92 | 12.34 | 18 | 37990 | 835 | 64459889 |
Hypoaesthesia | 46.88 | 12.34 | 184 | 37824 | 138924 | 64321800 |
Concussion | 46.29 | 12.34 | 38 | 37970 | 7900 | 64452824 |
Hot flush | 46.04 | 12.34 | 91 | 37917 | 46144 | 64414580 |
Application site exfoliation | 46.03 | 12.34 | 14 | 37994 | 317 | 64460407 |
Neutropenia | 46.03 | 12.34 | 44 | 37964 | 239580 | 64221144 |
Tension headache | 45.36 | 12.34 | 27 | 37981 | 3356 | 64457368 |
Renal infarct | 45.27 | 12.34 | 24 | 37984 | 2387 | 64458337 |
Renal impairment | 44.92 | 12.34 | 12 | 37996 | 135005 | 64325719 |
Application site dryness | 44.59 | 12.34 | 12 | 37996 | 172 | 64460552 |
Hostility | 44.38 | 12.34 | 23 | 37985 | 2184 | 64458540 |
Renal failure | 44.35 | 12.34 | 26 | 37982 | 181662 | 64279062 |
Incorrect route of product administration | 43.73 | 12.34 | 61 | 37947 | 23237 | 64437487 |
Libido increased | 42.87 | 12.34 | 21 | 37987 | 1769 | 64458955 |
Product substitution issue | 41.62 | 12.34 | 52 | 37956 | 17809 | 64442915 |
Sternal fracture | 41.16 | 12.34 | 22 | 37986 | 2225 | 64458499 |
Disease progression | 41.12 | 12.34 | 16 | 37992 | 141664 | 64319060 |
Device power source issue | 40.99 | 12.34 | 16 | 37992 | 778 | 64459946 |
Hyperkalaemia | 39.86 | 12.34 | 6 | 38002 | 101123 | 64359601 |
Hypotension | 38.39 | 12.34 | 107 | 37901 | 380867 | 64079857 |
Interstitial lung disease | 38.06 | 12.34 | 6 | 38002 | 97726 | 64362998 |
Pancytopenia | 37.16 | 12.34 | 19 | 37989 | 143290 | 64317434 |
Atrial fibrillation | 37.02 | 12.34 | 28 | 37980 | 171061 | 64289663 |
Drug specific antibody | 36.94 | 12.34 | 20 | 37988 | 2075 | 64458649 |
Platelet count decreased | 36.86 | 12.34 | 27 | 37981 | 167684 | 64293040 |
Infusion related reaction | 36.77 | 12.34 | 26 | 37982 | 164441 | 64296283 |
Injection site bruising | 35.50 | 12.34 | 71 | 37937 | 36302 | 64424422 |
Injury | 35.38 | 12.34 | 92 | 37916 | 55900 | 64404824 |
Clonus | 35.29 | 12.34 | 29 | 37979 | 6038 | 64454686 |
Hyponatraemia | 35.12 | 12.34 | 22 | 37986 | 148317 | 64312407 |
Angle closure glaucoma | 35.09 | 12.34 | 21 | 37987 | 2636 | 64458088 |
Drug hypersensitivity | 35.00 | 12.34 | 250 | 37758 | 237565 | 64223159 |
Feeling abnormal | 34.44 | 12.34 | 163 | 37845 | 133439 | 64327285 |
Multiple organ dysfunction syndrome | 33.76 | 12.34 | 9 | 37999 | 101404 | 64359320 |
Application site inflammation | 33.66 | 12.34 | 12 | 37996 | 452 | 64460272 |
Thrombocytopenia | 33.48 | 12.34 | 50 | 37958 | 223751 | 64236973 |
Septic shock | 32.12 | 12.34 | 11 | 37997 | 105426 | 64355298 |
Suicidal ideation | 31.95 | 12.34 | 99 | 37909 | 66443 | 64394281 |
Pain | 31.16 | 12.34 | 478 | 37530 | 553033 | 63907691 |
Pharyngeal swelling | 31.14 | 12.34 | 26 | 37982 | 5533 | 64455191 |
Palpitations | 31.07 | 12.34 | 133 | 37875 | 104355 | 64356369 |
Photophobia | 30.57 | 12.34 | 44 | 37964 | 17249 | 64443475 |
Vision blurred | 30.03 | 12.34 | 119 | 37889 | 90197 | 64370527 |
Application site scab | 29.75 | 12.34 | 9 | 37999 | 200 | 64460524 |
Haemoglobin decreased | 29.74 | 12.34 | 43 | 37965 | 195020 | 64265704 |
Treatment failure | 29.53 | 12.34 | 16 | 37992 | 116800 | 64343924 |
Nightmare | 29.47 | 12.34 | 48 | 37960 | 20945 | 64439779 |
Expired product administered | 29.47 | 12.34 | 26 | 37982 | 5961 | 64454763 |
Gastrointestinal haemorrhage | 29.46 | 12.34 | 21 | 37987 | 132291 | 64328433 |
Transient global amnesia | 29.06 | 12.34 | 12 | 37996 | 676 | 64460048 |
Blood creatinine increased | 28.38 | 12.34 | 23 | 37985 | 135759 | 64324965 |
Pleural effusion | 28.30 | 12.34 | 20 | 37988 | 126539 | 64334185 |
Application site bruise | 28.20 | 12.34 | 9 | 37999 | 240 | 64460484 |
Subclavian artery thrombosis | 27.89 | 12.34 | 6 | 38002 | 30 | 64460694 |
Malignant neoplasm progression | 27.75 | 12.34 | 16 | 37992 | 112855 | 64347869 |
Secondary adrenocortical insufficiency | 27.05 | 12.34 | 17 | 37991 | 2328 | 64458396 |
Hyperprolactinaemia | 26.99 | 12.34 | 21 | 37987 | 4044 | 64456680 |
Off label use | 26.49 | 12.34 | 242 | 37766 | 632564 | 63828160 |
Pyrexia | 26.36 | 12.34 | 207 | 37801 | 558437 | 63902287 |
Personality disorder | 26.32 | 12.34 | 22 | 37986 | 4689 | 64456035 |
Product adhesion issue | 26.31 | 12.34 | 17 | 37991 | 2442 | 64458282 |
Product leakage | 26.19 | 12.34 | 11 | 37997 | 647 | 64460077 |
Device leakage | 25.85 | 12.34 | 28 | 37980 | 8238 | 64452486 |
Vasospasm | 25.49 | 12.34 | 12 | 37996 | 926 | 64459798 |
Therapeutic response unexpected | 25.41 | 12.34 | 40 | 37968 | 16961 | 64443763 |
Lower respiratory tract infection | 25.35 | 12.34 | 12 | 37996 | 94602 | 64366122 |
Application site reaction | 25.31 | 12.34 | 11 | 37997 | 704 | 64460020 |
Application site discomfort | 25.19 | 12.34 | 9 | 37999 | 341 | 64460383 |
Cardiac failure congestive | 25.02 | 12.34 | 24 | 37984 | 130556 | 64330168 |
Hyperhidrosis | 24.97 | 12.34 | 142 | 37866 | 124778 | 64335946 |
Incorrect dose administered by device | 24.71 | 12.34 | 20 | 37988 | 4077 | 64456647 |
Somnambulism | 24.65 | 12.34 | 22 | 37986 | 5119 | 64455605 |
Migraine without aura | 24.56 | 12.34 | 8 | 38000 | 228 | 64460496 |
Temperature intolerance | 24.15 | 12.34 | 27 | 37981 | 8228 | 64452496 |
Respiratory failure | 24.10 | 12.34 | 36 | 37972 | 161147 | 64299577 |
Insomnia | 24.08 | 12.34 | 199 | 37809 | 197637 | 64263087 |
Cerebral venous thrombosis | 23.99 | 12.34 | 16 | 37992 | 2425 | 64458299 |
Muscle spasms | 23.55 | 12.34 | 153 | 37855 | 140870 | 64319854 |
Dysgeusia | 23.52 | 12.34 | 71 | 37937 | 46976 | 64413748 |
Poor quality sleep | 23.50 | 12.34 | 41 | 37967 | 18910 | 64441814 |
Electrocardiogram ST segment elevation | 23.42 | 12.34 | 25 | 37983 | 7234 | 64453490 |
Drug dependence | 23.41 | 12.34 | 57 | 37951 | 33255 | 64427469 |
Renal tubular acidosis | 23.36 | 12.34 | 17 | 37991 | 2962 | 64457762 |
Vasoconstriction | 23.34 | 12.34 | 10 | 37998 | 618 | 64460106 |
Memory impairment | 23.15 | 12.34 | 106 | 37902 | 85576 | 64375148 |
Glossodynia | 22.98 | 12.34 | 5 | 38003 | 64691 | 64396033 |
Paraesthesia oral | 22.61 | 12.34 | 33 | 37975 | 13098 | 64447626 |
Infection | 22.48 | 12.34 | 47 | 37961 | 184833 | 64275891 |
Phonophobia | 22.42 | 12.34 | 9 | 37999 | 471 | 64460253 |
Neck pain | 22.02 | 12.34 | 83 | 37925 | 61450 | 64399274 |
Wound | 21.59 | 12.34 | 9 | 37999 | 76468 | 64384256 |
Gallbladder disorder | 21.32 | 12.34 | 37 | 37971 | 16993 | 64443731 |
Head discomfort | 20.75 | 12.34 | 30 | 37978 | 11804 | 64448920 |
Myofascial pain syndrome | 20.65 | 12.34 | 13 | 37995 | 1785 | 64458939 |
Product complaint | 20.52 | 12.34 | 30 | 37978 | 11924 | 64448800 |
Therapeutic product effect incomplete | 20.26 | 12.34 | 117 | 37891 | 103365 | 64357359 |
Middle insomnia | 20.23 | 12.34 | 31 | 37977 | 12846 | 64447878 |
Tremor | 20.17 | 12.34 | 153 | 37855 | 148077 | 64312647 |
Migraine with aura | 19.98 | 12.34 | 14 | 37994 | 2298 | 64458426 |
Pharyngeal oedema | 19.78 | 12.34 | 34 | 37974 | 15497 | 64445227 |
International normalised ratio increased | 19.78 | 12.34 | 11 | 37997 | 79156 | 64381568 |
Application site papules | 19.71 | 12.34 | 5 | 38003 | 56 | 64460668 |
Diarrhoea | 19.59 | 12.34 | 304 | 37704 | 722400 | 63738324 |
Burns second degree | 19.49 | 12.34 | 10 | 37998 | 930 | 64459794 |
Basilar migraine | 19.47 | 12.34 | 5 | 38003 | 59 | 64460665 |
Burning sensation | 19.47 | 12.34 | 69 | 37939 | 49595 | 64411129 |
Decreased appetite | 19.08 | 12.34 | 93 | 37915 | 281196 | 64179528 |
Oxygen saturation decreased | 19.06 | 12.34 | 21 | 37987 | 107155 | 64353569 |
Meningitis aseptic | 18.96 | 12.34 | 20 | 37988 | 5710 | 64455014 |
Irritability | 18.88 | 12.34 | 56 | 37952 | 36690 | 64424034 |
Flushing | 18.85 | 12.34 | 94 | 37914 | 78554 | 64382170 |
Epistaxis | 18.84 | 12.34 | 18 | 37990 | 98113 | 64362611 |
Xanthelasma | 18.80 | 12.34 | 6 | 38002 | 160 | 64460564 |
Hyperreflexia | 18.58 | 12.34 | 22 | 37986 | 7126 | 64453598 |
Dependence | 18.51 | 12.34 | 13 | 37995 | 2142 | 64458582 |
Facial pain | 18.41 | 12.34 | 23 | 37985 | 7872 | 64452852 |
Drug effect less than expected | 18.30 | 12.34 | 8 | 38000 | 519 | 64460205 |
Pre-existing condition improved | 18.26 | 12.34 | 18 | 37990 | 4744 | 64455980 |
Post-traumatic stress disorder | 18.22 | 12.34 | 17 | 37991 | 4188 | 64456536 |
Aphasia | 17.93 | 12.34 | 59 | 37949 | 40847 | 64419877 |
Peripheral coldness | 17.65 | 12.34 | 30 | 37978 | 13554 | 64447170 |
Blood bilirubin increased | 17.53 | 12.34 | 6 | 38002 | 57547 | 64403177 |
Ovarian neoplasm | 17.53 | 12.34 | 8 | 38000 | 575 | 64460149 |
Biliary dyskinesia | 17.39 | 12.34 | 13 | 37995 | 2359 | 64458365 |
Loss of consciousness | 17.38 | 12.34 | 148 | 37860 | 148217 | 64312507 |
Visual impairment | 17.37 | 12.34 | 88 | 37920 | 73989 | 64386735 |
Hyperacusis | 17.33 | 12.34 | 12 | 37996 | 1933 | 64458791 |
Transverse sinus thrombosis | 17.06 | 12.34 | 8 | 38000 | 612 | 64460112 |
Application site erosion | 17.01 | 12.34 | 6 | 38002 | 219 | 64460505 |
Gastrooesophageal reflux disease | 16.93 | 12.34 | 95 | 37913 | 83048 | 64377676 |
Burns third degree | 16.82 | 12.34 | 7 | 38001 | 402 | 64460322 |
Bone marrow failure | 16.45 | 12.34 | 4 | 38004 | 47948 | 64412776 |
Superior sagittal sinus thrombosis | 16.33 | 12.34 | 9 | 37999 | 967 | 64459757 |
Withdrawal syndrome | 16.30 | 12.34 | 40 | 37968 | 23452 | 64437272 |
Lactic acidosis | 16.12 | 12.34 | 8 | 38000 | 61402 | 64399322 |
Injection site laceration | 16.08 | 12.34 | 5 | 38003 | 122 | 64460602 |
Multiple sclerosis relapse | 15.99 | 12.34 | 57 | 37951 | 41078 | 64419646 |
Rheumatoid arthritis | 15.88 | 12.34 | 47 | 37961 | 164247 | 64296477 |
Injection site erythema | 15.83 | 12.34 | 83 | 37925 | 70717 | 64390007 |
Aspartate aminotransferase increased | 15.81 | 12.34 | 29 | 37979 | 119759 | 64340965 |
Haematuria | 15.69 | 12.34 | 8 | 38000 | 60463 | 64400261 |
Hypoglycaemia | 15.56 | 12.34 | 18 | 37990 | 89874 | 64370850 |
Meningoradiculitis | 15.50 | 12.34 | 5 | 38003 | 138 | 64460586 |
Cerebral venous sinus thrombosis | 15.49 | 12.34 | 11 | 37997 | 1844 | 64458880 |
Sunburn | 15.47 | 12.34 | 14 | 37994 | 3318 | 64457406 |
Large intestinal ulcer haemorrhage | 15.40 | 12.34 | 6 | 38002 | 290 | 64460434 |
General physical health deterioration | 15.40 | 12.34 | 65 | 37943 | 204360 | 64256364 |
Pancreatic failure | 15.39 | 12.34 | 10 | 37998 | 1450 | 64459274 |
Blood pressure systolic increased | 15.34 | 12.34 | 5 | 38003 | 49448 | 64411276 |
Post viral fatigue syndrome | 15.25 | 12.34 | 6 | 38002 | 298 | 64460426 |
Systemic lupus erythematosus | 15.18 | 12.34 | 14 | 37994 | 77598 | 64383126 |
Toxicity to various agents | 15.17 | 12.34 | 139 | 37869 | 363374 | 64097350 |
Deep vein thrombosis | 15.11 | 12.34 | 110 | 37898 | 105072 | 64355652 |
Gallbladder injury | 14.97 | 12.34 | 9 | 37999 | 1139 | 64459585 |
Neoplasm progression | 14.89 | 12.34 | 3 | 38005 | 40961 | 64419763 |
Gastrointestinal tract irritation | 14.88 | 12.34 | 7 | 38001 | 539 | 64460185 |
Incorrect disposal of product | 14.73 | 12.34 | 8 | 38000 | 835 | 64459889 |
Torsade de pointes | 14.73 | 12.34 | 32 | 37976 | 17331 | 64443393 |
Cardio-respiratory arrest | 14.68 | 12.34 | 22 | 37986 | 98371 | 64362353 |
Incorrect product administration duration | 14.64 | 12.34 | 23 | 37985 | 9735 | 64450989 |
Device difficult to use | 14.57 | 12.34 | 23 | 37985 | 9775 | 64450949 |
Vertigo | 14.47 | 12.34 | 71 | 37937 | 58940 | 64401784 |
Impaired healing | 14.26 | 12.34 | 9 | 37999 | 60464 | 64400260 |
Needle issue | 14.11 | 12.34 | 22 | 37986 | 9250 | 64451474 |
Pericardial effusion | 14.01 | 12.34 | 3 | 38005 | 39251 | 64421473 |
Major depression | 13.98 | 12.34 | 20 | 37988 | 7796 | 64452928 |
Therapeutic response shortened | 13.93 | 12.34 | 23 | 37985 | 10147 | 64450577 |
Hormone level abnormal | 13.92 | 12.34 | 10 | 37998 | 1707 | 64459017 |
Peripheral nerve injury | 13.87 | 12.34 | 7 | 38001 | 629 | 64460095 |
Eyelid ptosis | 13.67 | 12.34 | 22 | 37986 | 9503 | 64451221 |
Injection site urticaria | 13.62 | 12.34 | 24 | 37984 | 11157 | 64449567 |
Haemorrhage | 13.61 | 12.34 | 16 | 37992 | 79335 | 64381389 |
Bradycardia | 13.58 | 12.34 | 31 | 37977 | 118188 | 64342536 |
Contraindicated product administered | 13.45 | 12.34 | 27 | 37981 | 107802 | 64352922 |
Nasal oedema | 13.40 | 12.34 | 8 | 38000 | 1000 | 64459724 |
Eye pain | 13.32 | 12.34 | 45 | 37963 | 31580 | 64429144 |
Alanine aminotransferase increased | 13.27 | 12.34 | 40 | 37968 | 138991 | 64321733 |
Lichen planus | 13.27 | 12.34 | 11 | 37997 | 2317 | 64458407 |
Product dispensing error | 13.21 | 12.34 | 24 | 37984 | 11426 | 64449298 |
Complement factor C4 decreased | 13.01 | 12.34 | 5 | 38003 | 233 | 64460491 |
Cytomegalovirus infection | 12.96 | 12.34 | 3 | 38005 | 37196 | 64423528 |
Underdose | 12.92 | 12.34 | 39 | 37969 | 25790 | 64434934 |
Choking sensation | 12.89 | 12.34 | 13 | 37995 | 3522 | 64457202 |
Arthropathy | 12.89 | 12.34 | 33 | 37975 | 120934 | 64339790 |
Capillaritis | 12.89 | 12.34 | 5 | 38003 | 239 | 64460485 |
Panic attack | 12.79 | 12.34 | 34 | 37974 | 20919 | 64439805 |
Neutrophil count decreased | 12.78 | 12.34 | 16 | 37992 | 77180 | 64383544 |
Body temperature increased | 12.74 | 12.34 | 49 | 37959 | 36617 | 64424107 |
Trismus | 12.60 | 12.34 | 15 | 37993 | 4886 | 64455838 |
Seizure | 12.56 | 12.34 | 152 | 37856 | 166740 | 64293984 |
Hepatotoxicity | 12.46 | 12.34 | 4 | 38004 | 39958 | 64420766 |
Slow speech | 12.40 | 12.34 | 10 | 37998 | 2027 | 64458697 |
None
Source | Code | Description |
---|---|---|
ATC | N02CC01 | NERVOUS SYSTEM ANALGESICS ANTIMIGRAINE PREPARATIONS Selective serotonin (5HT1) agonists |
CHEBI has role | CHEBI:35941 | serotonin agonists |
FDA MoA | N0000175763 | Serotonin 1b Receptor Agonists |
FDA MoA | N0000175764 | Serotonin 1d Receptor Agonists |
FDA EPC | N0000175765 | Serotonin-1b and Serotonin-1d Receptor Agonist |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D058825 | Serotonin 5-HT1 Receptor Agonists |
MeSH PA | D018490 | Serotonin Agents |
MeSH PA | D017366 | Serotonin Receptor Agonists |
MeSH PA | D014662 | Vasoconstrictor Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Migraine | indication | 37796009 | DOID:6364 |
Cluster headache syndrome | indication | 193031009 | |
Tachyarrhythmia | contraindication | 6285003 | |
Alcoholism | contraindication | 7200002 | |
Hypercholesterolemia | contraindication | 13644009 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Gastrointestinal ulcer | contraindication | 40845000 | |
Body fluid retention | contraindication | 43498006 | |
Chronic heart failure | contraindication | 48447003 | |
Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
Hemiplegic migraine | contraindication | 59292006 | |
Hepatic failure | contraindication | 59927004 | |
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Gastrointestinal hemorrhage | contraindication | 74474003 | |
Vascular insufficiency of intestine | contraindication | 82196007 | |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Prinzmetal angina | contraindication | 87343002 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Liver function tests abnormal | contraindication | 166603001 | |
Angina pectoris | contraindication | 194828000 | |
Cerebrovascular accident | contraindication | 230690007 | |
Coronary artery bypass graft | contraindication | 232717009 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Transient ischemic attack | contraindication | 266257000 | DOID:224 |
Esophageal dysmotility | contraindication | 266434009 | DOID:9192 |
Edema | contraindication | 267038008 | |
Anemia | contraindication | 271737000 | DOID:2355 |
Cerebral ischemia | contraindication | 287731003 | |
Pregnancy, function | contraindication | 289908002 | |
Thromboembolic disorder | contraindication | 371039008 | |
Serotonin syndrome | contraindication | 371089000 | |
Cardiovascular event risk | contraindication | 395112001 | |
Peripheral vascular disease | contraindication | 400047006 | |
Disorder of coronary artery | contraindication | 414024009 | |
Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
Obesity | contraindication | 414916001 | DOID:9970 |
Hypertensive urgency | contraindication | 443482000 | |
Smokes tobacco daily | contraindication | 449868002 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 11.23 | acidic |
pKa2 | 13.42 | acidic |
pKa3 | 8.28 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 8327844 | Oct. 3, 2023 | METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 7975690 | Aug. 18, 2025 | METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 8590530 | Sept. 15, 2025 | METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY |
500MG;EQ 85MG BASE | TREXIMET | CURRAX | N021926 | April 15, 2008 | RX | TABLET | ORAL | 7332183 | Oct. 2, 2025 | TREATMENT OF MIGRAINE |
60MG;EQ 10MG BASE | TREXIMET | CURRAX | N021926 | May 14, 2015 | DISCN | TABLET | ORAL | 7332183 | Oct. 2, 2025 | ACUTE TREATMENT OF MIGRAINE |
10MG/SPRAY | TOSYMRA | UPSHER SMITH LABS | N210884 | Jan. 25, 2019 | RX | SPRAY | NASAL | 8440631 | May 9, 2026 | ACUTE TREATMENT OF MIGRAINE |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 10124132 | March 6, 2027 | ACUTE TREATMENT OF MIGRAINE |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 10124132 | March 6, 2027 | ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 10124132 | March 6, 2027 | TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY |
EQ 6.5MG BASE/4HR | ZECUITY | TEVA BRANDED PHARM | N202278 | Jan. 17, 2013 | DISCN | SYSTEM | IONTOPHORESIS | 7973058 | April 12, 2027 | METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF |
EQ 6.5MG BASE/4HR | ZECUITY | TEVA BRANDED PHARM | N202278 | Jan. 17, 2013 | DISCN | SYSTEM | IONTOPHORESIS | 8155737 | April 12, 2027 | METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF |
EQ 6.5MG BASE/4HR | ZECUITY | TEVA BRANDED PHARM | N202278 | Jan. 17, 2013 | DISCN | SYSTEM | IONTOPHORESIS | 8470853 | April 12, 2027 | METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF |
EQ 6.5MG BASE/4HR | ZECUITY | TEVA BRANDED PHARM | N202278 | Jan. 17, 2013 | DISCN | SYSTEM | IONTOPHORESIS | 9427578 | April 12, 2027 | METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF |
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | ALSUMA | MERIDIAN MEDCL | N022377 | June 29, 2010 | DISCN | INJECTABLE | SUBCUTANEOUS | 7811254 | Aug. 26, 2027 | ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 8875704 | April 7, 2028 | METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY |
EQ 6.5MG BASE/4HR | ZECUITY | TEVA BRANDED PHARM | N202278 | Jan. 17, 2013 | DISCN | SYSTEM | IONTOPHORESIS | 8366600 | April 21, 2029 | METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 10076615 | July 30, 2029 | ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 10076615 | July 30, 2029 | METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 10076615 | July 30, 2029 | TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY |
10MG/SPRAY | TOSYMRA | UPSHER SMITH LABS | N210884 | Jan. 25, 2019 | RX | SPRAY | NASAL | 10603305 | June 16, 2030 | ACUTE TREATMENT OF MIGRAINE |
10MG/SPRAY | TOSYMRA | UPSHER SMITH LABS | N210884 | Jan. 25, 2019 | RX | SPRAY | NASAL | 11337962 | June 16, 2030 | ACUTE TREATMENT OF MIGRAINE |
10MG/SPRAY | TOSYMRA | UPSHER SMITH LABS | N210884 | Jan. 25, 2019 | RX | SPRAY | NASAL | 9610280 | June 16, 2030 | ACUTE TREATMENT OF MIGRAINE |
10MG/SPRAY | TOSYMRA | UPSHER SMITH LABS | N210884 | Jan. 25, 2019 | RX | SPRAY | NASAL | 9974770 | June 16, 2030 | ACUTE TREATMENT OF MIGRAINE |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 9649456 | Oct. 21, 2030 | ACUTE TREATMENT OF MIGRAINE |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 9649456 | Oct. 21, 2030 | ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 9649456 | Oct. 21, 2030 | TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY |
EQ 6.5MG BASE/4HR | ZECUITY | TEVA BRANDED PHARM | N202278 | Jan. 17, 2013 | DISCN | SYSTEM | IONTOPHORESIS | 8983594 | Nov. 19, 2030 | METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF |
10MG/SPRAY | TOSYMRA | UPSHER SMITH LABS | N210884 | Jan. 25, 2019 | RX | SPRAY | NASAL | 9211282 | July 19, 2031 | ACUTE TREATMENT OF MIGRAINE |
EQ 6.5MG BASE/4HR | ZECUITY | TEVA BRANDED PHARM | N202278 | Jan. 17, 2013 | DISCN | SYSTEM | IONTOPHORESIS | 9327114 | Oct. 8, 2032 | METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 10478574 | Nov. 4, 2033 | METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY |
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) | ZEMBRACE SYMTOUCH | UPSHER SMITH LABS | N208223 | Jan. 28, 2016 | RX | SOLUTION | SUBCUTANEOUS | 10537554 | Jan. 29, 2036 | TREATMENT OF MIGRAINE |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
5-hydroxytryptamine receptor 1D | GPCR | AGONIST | Ki | 8.92 | CHEMBL | CHEMBL | |||
5-hydroxytryptamine receptor 1B | GPCR | AGONIST | Ki | 8.26 | CHEMBL | CHEMBL | |||
5-hydroxytryptamine receptor 2C | GPCR | IC50 | 8.14 | CHEMBL | |||||
5-hydroxytryptamine receptor 6 | GPCR | ANTAGONIST | Ki | 5.60 | IUPHAR | ||||
5-hydroxytryptamine receptor 7 | GPCR | ANTAGONIST | Ki | 6 | IUPHAR | ||||
5-hydroxytryptamine receptor 3A | Ion channel | IC50 | 8.03 | CHEMBL | |||||
5-hydroxytryptamine receptor 5A | GPCR | IC50 | 6.30 | CHEMBL | |||||
5-hydroxytryptamine receptor 1F | GPCR | Ki | 7.59 | CHEMBL | |||||
5-hydroxytryptamine receptor 1E | GPCR | IC50 | 5.26 | CHEMBL | |||||
Multidrug and toxin extrusion protein 1 | Transporter | IC50 | 5.17 | CHEMBL | |||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 6.64 | CHEMBL | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 6.42 | CHEMBL | |||||
5-hydroxytryptamine receptor 1B | GPCR | Ki | 7.64 | CHEMBL | |||||
5-hydroxytryptamine receptor 1A | GPCR | IC50 | 6.19 | CHEMBL | |||||
5-hydroxytryptamine receptor 7 | GPCR | ANTAGONIST | Ki | 6.60 | IUPHAR | ||||
5-hydroxytryptamine receptor 1D | GPCR | IC50 | 7.70 | CHEMBL | |||||
5-hydroxytryptamine receptor 1A | GPCR | IC50 | 6.35 | CHEMBL | |||||
5-hydroxytryptamine receptor 1D | GPCR | IC50 | 7.21 | CHEMBL | |||||
5-hydroxytryptamine receptor 6 | GPCR | ANTAGONIST | Ki | 5.20 | IUPHAR | ||||
5-hydroxytryptamine receptor 1B | GPCR | Ki | 8.19 | CHEMBL | |||||
5-hydroxytryptamine 1D receptor | Unclassified | IC50 | 7.23 | CHEMBL | |||||
5-hydroxytryptamine receptor 5A | GPCR | AGONIST | Ki | 4.80 | IUPHAR |
ID | Source |
---|---|
4021050 | VUID |
N0000148514 | NUI |
D00451 | KEGG_DRUG |
103628-48-4 | SECONDARY_CAS_RN |
4020790 | VANDF |
4021050 | VANDF |
C0075632 | UMLSCUI |
CHEBI:10650 | CHEBI |
CHEMBL128 | ChEMBL_ID |
DB00669 | DRUGBANK_ID |
CHEMBL1201150 | ChEMBL_ID |
D018170 | MESH_DESCRIPTOR_UI |
5358 | PUBCHEM_CID |
54 | IUPHAR_LIGAND_ID |
6125 | INN_ID |
8R78F6L9VO | UNII |
37418 | RXNORM |
158892 | MMSL |
166806 | MMSL |
25268 | MMSL |
31925 | MMSL |
5536 | MMSL |
d03160 | MMSL |
004044 | NDDF |
004045 | NDDF |
322822007 | SNOMEDCT_US |
395892000 | SNOMEDCT_US |
96215002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Sumatriptan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2013 | INJECTION | 4 mg | SUBCUTANEOUS | ANDA | 28 sections |
Sumatriptan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2014 | INJECTION | 6 mg | SUBCUTANEOUS | ANDA | 28 sections |
SUMATRIPTAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9638 | INJECTION | 6 mg | SUBCUTANEOUS | ANDA | 27 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0478 | INJECTION | 6 mg | SUBCUTANEOUS | NDA | 28 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0479 | INJECTION | 6 mg | SUBCUTANEOUS | NDA | 28 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0523 | SPRAY | 20 mg | NASAL | NDA | 27 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0524 | SPRAY | 5 mg | NASAL | NDA | 27 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0735 | TABLET, FILM COATED | 25 mg | ORAL | NDA | 27 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0736 | TABLET, FILM COATED | 50 mg | ORAL | NDA | 27 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0737 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 27 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0739 | INJECTION | 4 mg | SUBCUTANEOUS | NDA | 28 sections |
ZEMBRACE SYMTOUCH | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0245-0809 | INJECTION, SOLUTION | 3 mg | SUBCUTANEOUS | NDA | 31 sections |
TOSYMRA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0245-0812 | SPRAY | 10 mg | NASAL | NDA | 31 sections |
Sumatriptan Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-5630 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 28 sections |
Sumatriptan Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-5631 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 28 sections |
Sumatriptan Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-5632 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 28 sections |
Sumatriptan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1818 | SPRAY | 5 mg | NASAL | ANDA | 28 sections |
Sumatriptan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1859 | SPRAY | 20 mg | NASAL | ANDA | 28 sections |
Sumatriptan Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-300 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 13 sections |
SUMATRIPTAN SUCCINATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-408 | TABLET | 50 mg | ORAL | ANDA | 27 sections |
SUMATRIPTAN SUCCINATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-950 | TABLET | 25 mg | ORAL | ANDA | 27 sections |
Sumatriptan Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-040 | INJECTION | 6 mg | SUBCUTANEOUS | ANDA | 27 sections |
Sumatriptan | Human Prescription Drug Label | 1 | 16714-796 | TABLET | 25 mg | ORAL | ANDA | 27 sections |
Sumatriptan | Human Prescription Drug Label | 1 | 16714-797 | TABLET | 50 mg | ORAL | ANDA | 27 sections |
Sumatriptan | Human Prescription Drug Label | 1 | 16714-798 | TABLET | 100 mg | ORAL | ANDA | 27 sections |
Sumatriptan and Naproxen Sodium | Human Prescription Drug Label | 2 | 16714-891 | TABLET, FILM COATED | 85 mg | ORAL | ANDA | 32 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-154 | TABLET, FILM COATED | 50 mg | ORAL | NDA | 26 sections |
Sumatriptan Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-872 | TABLET | 25 mg | ORAL | ANDA | 27 sections |
Sumatriptan Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-873 | TABLET | 50 mg | ORAL | ANDA | 27 sections |
Sumatriptan Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-874 | TABLET | 100 mg | ORAL | ANDA | 27 sections |